Literature DB >> 34352197

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.

Aurélie Truffot, Julien Andréani, Marion Le Maréchal, Alban Caporossi, Olivier Epaulard, Raphaele Germi, Pascal Poignard, Sylvie Larrat.   

Abstract

A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleotide polymorphisms and whole-genome sequencing. Rapid emergence of spike receptor binding domain mutations was found, associated with a compartmentalization of viral populations.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; bamlanivimab; compartmentalization; coronavirus disease; coronaviruses; immunotherapy; monoclonal antibody; monotherapy; respiratory infections; selection; severe acute respiratory syndrome coronavirus 2; variants; viruses; whole-genome sequencing; zoonoses

Year:  2021        PMID： 34352197     DOI： 10.3201/eid2710.211509

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN： 1080-6040            Impact factor:   6.883


  7 in total

Review 1.  Identifying Markers of Emerging SARS-CoV-2 Variants in Patients With Secondary Immunodeficiency.

Authors:  Nathan M Markarian; Gaël Galli; Dhanesh Patel; Mark Hemmings; Priya Nagpal; Albert M Berghuis; Levon Abrahamyan; Silvia M Vidal
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

2.  Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022.

Authors:  Slim Fourati; Guillaume Gautier; Myriam Chovelon; Alexandre Soulier; Melissa N'Debi; Vanessa Demontant; Céline Kennel; Christophe Rodriguez; Jean-Michel Pawlotsky
Journal:  Emerg Infect Dis       Date:  2022-05-06       Impact factor: 16.126

3.  Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.

Authors:  Yotam Bronstein; Amos Adler; Haytham Katash; Ora Halutz; Yair Herishanu; Katia Levytskyi
Journal:  J Med Virol       Date:  2021-11-13       Impact factor: 20.693

4.  Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review.

Authors:  Daniele Focosi; Fabrizio Maggi; Massimo Franchini; Scott McConnell; Arturo Casadevall
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

5.  XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.

Authors:  Bernard Vanhove; Stéphane Marot; Ray T So; Benjamin Gaborit; Gwénaëlle Evanno; Isabelle Malet; Guillaume Lafrogne; Edwige Mevel; Carine Ciron; Pierre-Joseph Royer; Elsa Lheriteau; François Raffi; Roberto Bruzzone; Chris Ka Pun Mok; Odile Duvaux; Anne-Geneviève Marcelin; Vincent Calvez
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

Review 6.  Spike protein of SARS-CoV-2 variants: a brief review and practical implications.

Authors:  Kattlyn Laryssa Candido; Caio Ricardo Eich; Luciana Oliveira de Fariña; Marina Kimiko Kadowaki; José Luis da Conceição Silva; Alexandre Maller; Rita de Cássia Garcia Simão
Journal:  Braz J Microbiol       Date:  2022-04-09       Impact factor: 2.214

Review 7.  The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies.

Authors:  Daniele Focosi; Scott McConnell; Arturo Casadevall
Journal:  Drug Resist Updat       Date:  2022-10-03       Impact factor: 22.841
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.